|
 |
Home > GERMANY > Ausstellungsraum
SORIN, THE NEW " ZERO IMPACT" HEART VALVE
Rome, (Ign) - A world leader in in the market of Cardiac Surgery, which has built its success on increasingly advanced technology aimed at optimising the product-client relationship, of capital importance in the field of medicine. This is the Sorin Group (www.sorin.com), an Italian multinational working in the sector of medical technologies, which has recently announced the imminent release of a revolutionary percutaneous valve. This is a product that can be implanted in the patient without opening the chest or stopping the heart, and therefore eliminating the need for any surgical suturing. It is a valve built using biological materials, whose basic concept has already been implemented and experimented thanks to its use in other medical techniques for around a decade. The long period of incubation has made it possible to demonstrate its reliability scientifically, about which there are no longer any doubts.
The revolution, however, will also and above all regard the method with which these regulators are inserted in the patient's body: positioning will take place by means of vascular access or however using minimum invasive techniques (such as for example in an incision a few centimetres long). Once it has reached its destination, the device is designed to dilate and assume its final position, anchoring itself to the walls from which it cannot then be moved thanks above all to its particular form and the elastic material used, the result of recent innovations in the field that Sorin itself has helped develop. This solution on one hand rewards the importance that the company has always given to technology, research and development, and on the other allows an improved postoperative course and a much less traumatic operation. The new valve, above all, will also be usable in procedures of conventional heart surgery, which will make it possible both to save time in suturing and to reduce the duration of hospital stay, eliminating all those factors which at present create a series of problems in terms of possible complications due to heart attacks.
The innovative change follows the path already followed by research in the biomedical field: increasingly less invasive and dynamic operation procedures, adaptable to the patient's characteristics. The aim of these efforts coincides with the almost complete limitation of surgical operations with incisions which provide for invasive actions such as external blood circulation. Thanks to the innovations that the company is planning, above all in fact the valve, it will be possible to perform less traumatic procedures without incisions. It is no coincidence that this new approach has been taken by a multinational which has made research its core value, and which boasts international business relations and a position in the sector of extreme importance. In the third quarter of 2006 the Sorin Group in fact recorded net earnings of €184.7 million, with growth compared to the same period in 2005 of 5.6%. Not to mention +30% in operating profits (namely €4.8m) and a net financial position of no less than €325.4m. The name has now become a guarantee of efficiency and safety the world over, so much so that recently the company enlarged its client portfolio by reaching the important Japanese market, on which it launched its first implants in the Alto2 line of implantable cardiac defibrillators.
The sector of biomedical technology thrives on innovation, which is why Sorin is one of the market leaders. The merit is entirely due to the product range, attentive both to technological components and biological aspects and aimed basically at reducing - if not eliminating - patient discomfort. This is the case of the single- and dual-chamber ICD defibrillators, of Radix, Flype and InPeria in the treatment of endovascular problems and of Bicarbon, Pericardom and Freedom Solo, cardiac valves allowing facilitated implantation and innovative functions.
|
|
|
